Xeltis launches aXess in Europe on 12-month patency data matching mature AVFs
The European pivotal readout reported patency comparable to matured fistulas and fewer reinterventions than historical grafts, but posted no numeric results or comparator arm alongside the launch.
Executive Summary
- Xeltis moved from a 12-month pivotal readout straight into European commercial sales, treating the data as sufficient to launch rather than as an interim signal.
- The disclosed results describe patency and reintervention performance in line with established fistulas and better than historical grafts, though the comparison rests on benchmarks rather than a matched control group.
- A device competing against arteriovenous fistulas and grafts in a field with few direct precedents now carries the burden of holding up its European result as the US pivotal trial builds toward its own readout.
- The pivotal study's own primary completion date has moved earlier and later across amendments while enrollment held flat, a pattern consistent with routine registry housekeeping rather than a program in distress.
The launch and the data behind it
Xeltis, a Netherlands-based device maker, announced the first commercial implantation of aXess on July 7, 2026, performed by Dr. Dominik Liebetrau at Artemed Klinikum Munich South in Germany. The company tied the launch directly to its European pivotal trial results, saying the 12-month data showed secondary patency comparable to matured arteriovenous fistulas (AVFs), lower reintervention rates, and higher infection resistance than historical arteriovenous graft (AVG) benchmarks. CEO Eliane Schutte called the implant the moment marking "the transition from clinical development into routine patient care". The July release itself carries no numeric results; the figures behind the claim were disclosed earlier, at the 48th Charing Cross Symposium on April 21, 2026, where Xeltis reported 79% secondary patency at 12 months in 120 patients, a reintervention rate of 1.3 per patient-year, and a 3% access-related infection rate. XeltisXeltis makes first commercial implant of aXess™, its vascular access device for hemodialysisJul 7, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The regulatory basis
The commercial launch follows CE mark approval, granted after evaluation of the same pivotal dataset. No comparator arm ran alongside the aXess cohort in the pivotal study; the 79% patency figure and reintervention rate are stated against published historical benchmarks for AVGs rather than a randomized control group. The trial's registered primary endpoints are freedom from device-related serious adverse events during the first six months and primary patency rate, with patency and infection metrics carried as secondary endpoints. No p-values or confidence intervals accompanied either disclosure. NCT05473299Xeltis Hemodialysis Access Graft: aXess Pivotal StudyNCT05473299
Trial mechanics
The European pivotal study, NCT05473299, targeted 110 patients across nine countries including Germany, Italy, Spain, and the United Kingdom. The trial's status moved from Recruiting to Active, not recruiting in January 2025, alongside an enrollment update from 110 to 120 and a primary completion date shift from January 31, 2025 to June 30, 2025, later revised to June 23, 2025. The enrollment change registers as a routine adjustment rather than a shortfall against target. Xeltis said its separate US pivotal trial has now exceeded 50% enrollment, a study that will need to reproduce the European patency and reintervention profile to support a US filing. NCT05473299+1Xeltis Hemodialysis Access Graft: aXess Pivotal StudyNCT05473299Xeltis makes first commercial implant of aXess™, its vascular access device for hemodialysisJul 7, 2026
Where aXess sits in the field
Hemodialysis vascular access has no single dominant device competing directly with aXess's tissue-regenerating mechanism; the closest identified comparators in the same indication are other device-based approaches, including Humacyte's bioengineered vessel and dialyzer or catheter-focused programs, none of which share aXess's supramolecular scaffold mechanism. With no randomized head-to-head precedent for this device class in hemodialysis access, the result that would most clearly extend the European finding is a US pivotal readout that reproduces the same patency and reintervention profile under a comparator design rather than a benchmark comparison.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.